|Intitulé du poste:
||EU Medical Lead for Cemiplimab
||92 (Hauts-de-Seine) - Ile-de-France
||Sanofi - Gentilly, Val-de-Marne - #LI-EUR EU MEDICAL LEAD FOR CEMIPLIMAB About the Opportunity Sanofi Genzyme has recently gained marketing authorization approval for Libtayo (Cemiplimab) in Europe. Libtayo (Cemiplimab) is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. It’s the first and only approved drug for this common skin cancer, which is especially difficult to treat in advanced stages. The EU Medical Lead will support the launch of Cemiplimab in CSCC in Europe as well as prepare the pre-launch strategies and tactics for the new indications of Cemiplimab. The EU Medical Lead will be working closely with the Global Cemiplimab medical team as well as EU Commercial Lead for Cemiplimab. Location: Amsterdam or any major European city. About Sanofi Genzyme Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple scleros...